Checkpoint Therapeutics Inc (NASDAQ:CKPT)
| 3.21 BATS BZX Real-Time Price As of 2:42pm ET |  +0.05 / +1.58%Today’s Change | 2.16 Today|||52-Week Range 5.38 | +21.13% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $259.8M |
Company Description
Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio include CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in New York, NY.
Contact Information
Checkpoint Therapeutics, Inc. 2 Gansevoort Street New York New York 10014 |
Employees
Shareholders
| Individual stakeholders | 8.56% |
| Other institutional | 8.50% |
| Mutual fund holders | 4.71% |
Top Executives
| James F. Oliviero | President, Chief Executive Officer & Director |
| William Garrett Gray | Chief Financial Officer, Secretary & Treasurer |
| Jaclyn Jaffe | Investor Relations Contact |
